{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:20:03Z","timestamp":1762507203827,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2017.00258","type":"journal-article","created":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T07:49:45Z","timestamp":1506671385000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves\u2019 Disease"],"prefix":"10.3389","volume":"8","author":[{"given":"Jia","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1210\/jc.2012-2802","article-title":"A 2011 survey of clinical practice patterns in the management of Graves\u2019 disease","volume":"97","author":"Burch","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2013-1954","article-title":"Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis","volume":"98","author":"Sundaresh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","first-page":"CD003420","DOI":"10.1002\/14651858.CD003420.pub4","article-title":"Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism","volume":"1","author":"Abraham","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJM200102153440707","article-title":"Thyroid hormone and the cardiovascular system","volume":"344","author":"Klein","year":"2001","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1089\/thy.2005.15.1279","article-title":"Graves\u2019 disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery","volume":"15","author":"Abraham-Nordling","year":"2005","journal-title":"Thyroid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40618-014-0214-2","article-title":"Role of genetic and non-genetic factors in the etiology of Graves\u2019 disease","volume":"38","author":"Marino","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1210\/jc.2015-3644","article-title":"Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves\u2019 hyperthyroidism","volume":"101","author":"Vos","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000342621","article-title":"Genotype and phenotype predictors of relapse of Graves\u2019 disease after antithyroid drug withdrawal","volume":"1","author":"Wang","year":"2013","journal-title":"Eur Thyroid J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1055\/s-0029-1220902","article-title":"The T393C polymorphism of the Galphas gene (GNAS1) is associated with the course of Graves\u2019 disease","volume":"41","author":"Glowacka","year":"2009","journal-title":"Horm Metab Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1210\/jc.2006-2761","article-title":"Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves\u2019 disease relapse after antithyroid drug withdrawal: a follow-up study","volume":"92","author":"Wang","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1210\/jc.2007-0675","article-title":"Association between a C\/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves\u2019 hyperthyroidism after antithyroid withdrawal in Taiwanese","volume":"92","author":"Hsiao","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-0029-1211712","article-title":"Genetic markers in diagnosis and prediction of relapse in Graves\u2019 disease","volume":"104","author":"Badenhoop","year":"1996","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1210\/jc.85.3.1038","article-title":"Age and gender predict the outcome of treatment for Graves\u2019 hyperthyroidism","volume":"85","author":"Allahabadia","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1055\/s-0035-1555759","article-title":"Outcome prediction of treatment of Graves\u2019 hyperthyroidism with antithyroid drugs","volume":"47","author":"Piantanida","year":"2015","journal-title":"Horm Metab Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MED.0000000000000088","article-title":"Relapse following antithyroid drug therapy for Graves\u2019 hyperthyroidism","volume":"21","author":"Laurberg","year":"2014","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3813540","DOI":"10.1155\/2017\/3813540","article-title":"Antithyroid drug therapy for Graves\u2019 disease and implications for recurrence","volume":"2017","author":"Liu","year":"2017","journal-title":"Int J Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation","volume":"105","author":"Riley","year":"2005","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1073\/pnas.92.3.811","article-title":"CTLA4 mediates antigen-specific apoptosis of human T cells","volume":"92","author":"Gribben","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0154394","DOI":"10.1371\/journal.pone.0154394","article-title":"Association of cytotoxic T-lymphocyte-associated protein 4 (CTLA4) gene polymorphisms with autoimmune thyroid disease in children and adults: case-control study","volume":"11","author":"Ting","year":"2016","journal-title":"PLoS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e0149441","DOI":"10.1371\/journal.pone.0149441","article-title":"Association of cytotoxic T-lymphocyte antigen 4 (CTLA4) and thyroglobulin (TG) genetic variants with autoimmune hypothyroidism","volume":"11","author":"Patel","year":"2016","journal-title":"PLoS One"},{"key":"B22","doi-asserted-by":"publisher","first-page":"747816","DOI":"10.1155\/2015\/747816","article-title":"Cytotoxic T lymphocyte-associated antigen 4 gene polymorphisms and autoimmune thyroid diseases: an updated systematic review and cumulative meta-analysis","volume":"2015","author":"Hou","year":"2015","journal-title":"Int J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1210\/jcem.76.6.8501164","article-title":"Human histocompatibility leukocyte antigen-DQA1*0501 allele associated with genetic susceptibility to Graves\u2019 disease in a Caucasian population","volume":"76","author":"Yanagawa","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/1096-8628(20001218)95:5<432::AID-AJMG5>3.0.CO;2-7","article-title":"Primary role of the HLA class II DRB1*0301 allele in Graves disease","volume":"95","author":"Zamani","year":"2000","journal-title":"Am J Med Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/j.1365-2265.2007.02787.x","article-title":"Linkage of Graves\u2019 disease to the human leucocyte antigen region in the Chinese-Han population in Taiwan","volume":"66","author":"Chen","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e16635","DOI":"10.1371\/journal.pone.0016635","article-title":"Comprehensive genotyping in two homogeneous Graves\u2019 disease samples reveals major and novel HLA association alleles","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1210\/jcem.83.4.4732","article-title":"Detection of CD40 on human thyroid follicular cells: analysis of expression and function","volume":"83","author":"Metcalfe","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/thy.2005.15.239","article-title":"Immunoregulatory and susceptibility genes in thyroid and polyglandular autoimmunity","volume":"15","author":"Dittmar","year":"2005","journal-title":"Thyroid"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/thy.2005.15.1119","article-title":"Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves\u2019 disease","volume":"15","author":"Kurylowicz","year":"2005","journal-title":"Thyroid"},{"key":"B30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/j.1365-2265.2005.02279.x","article-title":"Lymphoid tyrosine phosphatase (PTPN22\/LYP) variant and Graves\u2019 disease in a Polish population: association and gene dose-dependent correlation with age of onset","volume":"62","author":"Skorka","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5862","DOI":"10.1210\/jc.2004-1108","article-title":"The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves\u2019 disease","volume":"89","author":"Velaga","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"542","DOI":"10.2174\/138920211798120772","article-title":"The genetic basis of Graves\u2019 disease","volume":"12","author":"Ploski","year":"2011","journal-title":"Curr Genomics"},{"key":"B33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/1055-9965.EPI-04-0720","article-title":"The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer","volume":"14","author":"Frey","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B34","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1210\/edrv-9-4-450","article-title":"Role of autoantibodies in the pathogenesis and association of endocrine autoimmune disorders","volume":"9","author":"Salvi","year":"1988","journal-title":"Endocr Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1530\/EJE-08-0410","article-title":"Association of CD40 and thyroglobulin genes with later-onset Graves\u2019 disease in Taiwanese patients","volume":"59","author":"Hsiao","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10238-008-0151-5","article-title":"Exon 33 T\/T genotype of the thyroglobulin gene is a susceptibility gene for Graves\u2019 disease in Taiwanese and exon 12 C\/C genotype protects against it","volume":"8","author":"Hsiao","year":"2008","journal-title":"Clin Exp Med"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2017.00258\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T07:49:48Z","timestamp":1506671388000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fendo.2017.00258\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,29]]},"references-count":36,"alternative-id":["10.3389\/fendo.2017.00258"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2017.00258","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2017,9,29]]},"article-number":"258"}}